NVNONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
enVVeno Medical Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$7.69+0.22 (+2.95%)
Close on Oct 19, 2026
- Market cap
- $5.16M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2016 to 2025
Gross margin
–
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -225.9% | -56.2% | |
| Return on assets | – | -130.8% | -52.3% | |
| Current ratio | – | 3.00 | 13.58 | |
| Interest coverage | – | – | – | |
| Capex to revenue | – | – | – | |
| Diluted shares | – | 0M | 1M |
Where the cash went
Fiscal 2021 to 2025, five years combined
enVVeno Medical generated $78.73M from operations and spent $558.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$78.73M
Used
$558.00K
Capital expenditure$558.00K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-24406.7%
×Asset turnover0.01×
×Equity multiplier2.31×
=Return on equity, FY2019-503.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2019 | -24406.7% | 0.01× | 2.31× | -503.9% |
| FY2018 | -6991.5% | 0.06× | -0.63× | 286.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$19.47M
- Cash generatingOperating cash flow above zero-$15.57M
- Return on assets improvedROA up on the prior year-44.9% → -43.3%
- Earnings backed by cashOperating cash flow above net income-$15.57M vs -$19.47M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose20.88 → 13.58
- No dilutionShare count did not rise0M → 1M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –